GenomeWeb featured Mammogen’s appointment of Elise Berman, M.D., as Chief Medical Officer. Dr. Berman previously served as a senior medical advisor to Mammogen and brings extensive experience across breast imaging, medical affairs, and clinical development. Her appointment supports Mammogen as the company continues advancing genTRU-breast™ through clinical validation and toward commercialization. Read the full article on GenomeWeb →

Mammogen was featured in GenomeWeb’s People News roundup highlighting recent leadership developments across the genomics and molecular diagnostics industry. The coverage includes Mammogen among several industry companies and highlights a recent addition to the company’s leadership team. Read the full article on GenomeWeb →

Mammogen was featured in BioWorld’s roundup of recent appointments and advancements across the biopharma and med-tech industries. The coverage includes Mammogen among a group of life sciences companies announcing new hires, promotions, and leadership developments. Read the full article on BioWorld →

Startup Researcher featured Mammogen following the company’s Series A financing of up to $30 million to accelerate the development and commercialization of its RNA-powered diagnostic platform. The article highlights genTRU-breast™, Mammogen’s blood-based molecular assay designed to complement traditional imaging and support earlier breast cancer detection, particularly for women with dense breast tissue. The coverage also explores Mammogen’s plans to use the financing to advance its pivotal clinical study, support regulatory activities, expand strategic partnerships, and prepare for future commercialization. Read the full article on Startup Researcher →

Femtech Insider featured Mammogen following the company’s Series A financing of up to $30 million to advance genTRU-breast™, its RNA-powered blood test designed to support earlier breast cancer detection in women with dense breast tissue. The article explores how genTRU-breast is being developed as a triage tool following mammography, with the potential to help women and their physicians make more informed decisions about supplemental imaging and biopsy. The coverage also highlights Mammogen’s clinical progress, including its ongoing pivotal study, and features insights from CEO Elizabeth Cormier-May on the impact earlier detection can have on treatment options. Read the full article on Femtech Insider →